Market research
ABCM Abcam PLC
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 6B
- P/E ratio
- 2399.0
- Analyst target
- 1902.05
- Dividend yield
- Not available
- Beta
- 0.86
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0003802040
- Market cap
- 6B
- P/E ratio
- 2399.0
- Analyst target
- 1902.05
- Dividend yield
- Not available
- Beta
- 0.86
About
About Abcam PLC
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam plc operates as a subsidiary of Danaher Corporation.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ABCM discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.6.
Based on the above factors, Abcam plc gets an overall score of 1/5.